We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 448.01 | 0 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 448.04 | 450.50 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 9.92B | 3.57B | 13.8610 | 32.32 | 115.4B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | 448.01 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/1/2024 | 20:07 | DJN | Vertex Pharmaceuticals Says FDA Approved Casgevy for TDT Patients |
| 13/12/2023 | 17:48 | DJN | Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update |
| 13/12/2023 | 15:49 | DJN | Vertex Pharmaceuticals Up Over 8%, on Track for Record High Close -- Data.. |
| 13/12/2023 | 14:49 | DJN | Editas Medicine Strikes License Deal With Vertex Pharmaceuticals |
| 08/12/2023 | 21:11 | DJN | Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for.. |
| 08/12/2023 | 16:46 | DJN | CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease |
| 29/11/2023 | 19:55 | DJN | Vertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from.. |
| 24/11/2023 | 15:06 | DJN | Vertex Pharmaceuticals Gets Regulatory OK to Extend Use to More Patients in.. |
| 23/11/2023 | 14:54 | DJN | Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young.. |
Vertex Pharmaceuticals (VRTX) Share Charts1 Year Vertex Pharmaceuticals Chart |
|
1 Month Vertex Pharmaceuticals Chart |
Intraday Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
